SYMBICORT 320/9 MCG DOSE
= Additional active ingredients
Budesonide (micronized) formoterol fumarate dihydrate.
PRESENTATION AND DOSSAGE
Bronchial asthma where combination treatment of corticosteroid and long-acting beta agonist is appropriate. Patients not adequately controlled with inhal. corticoster. and “as needed” inhal. short act. ?-agonists, or patients adequately controlled on both inhal. corticoster and long act ?-agonists.
Known hypersensitivity to components.
Patients should be advised to have their rescue medicdbation available at all times. Patients transferring from oral steroids may remain at risk of impaired adrenal reserve for a considerable time. The patient should be instructed to rinse the mouth with water after each dosing occasion. Caution in patients with thyrotoxicosis, phaeochromocytoma, diabetes mellitus, untreated hypokalaemia, hypertrophic obstructive cardiomyopathy, idiopathic subvalvular aortic stenosis, severe hypertension, aneurism or other severe cardiovascular disorders, when treating patients with prolongation of the QTc-interval. Additional blood glucose controls should be considered in diabetic patients. Pregnancy and lactation. Patients with lung tuberculosis and fungal and viral infections in the airways.
Headache, palpitations, tremor, candida infections in the oropharynx, mild irritation in the throat, coughing, hoarseness. Rare cases of bronchoconstriction have been reported. Nervousness, restlessness and depression, behavioral disturbances in children. Rare cases of cataract after prolonged use of corticosteroid aerosols have been reported.
Ketoconazole, beta adrenergic blockers (including eye drops), quindine, disopyramide, procainamide, phenothiazines, antihistamines (terfenadine). MAOI’s, tricyclic antidepressives. L-Dopa, L-thyroxine, oxytocin, alcohol. Anasthesia with halogenated hydrocarbons, digitalis glycosides.
MANUFACTURER & DISTRIBUTER:
License Holder: AstraZeneca Israel